NCT07463768 2026-03-11
MIVONU
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT06707493 2026-03-10
Ivosidenib as Post-HSCT Maintenance for AML
Massachusetts General Hospital
Phase 2 Recruiting
NCT07392242 2026-03-06
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07260175 2026-02-23
adIVO
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT07282262 2025-12-15
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04493164 2025-11-21
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04278781 2025-10-23
AG-120 in People With IDH1 Mutant Chondrosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06717958 2025-07-02
PIVOT
Technische Universität Dresden
Phase 2 Recruiting
NCT03503409 2025-05-18
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies
Phase 2 Active not recruiting
NCT05401097 2025-05-14
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT06593548 2024-09-19
Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT04044209 2022-01-20
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
Phase 2 Withdrawn